ALKS Rasio cepet Alkermes plc

Irish biopharma Alkermes plc (ALKS) is scaling profits by utilizing low-cost synthesis for drugs that are expensive to develop. Its CNS ecosystem ensures a steady patient inflow with minimal churn. Strong pricing power within the schizophrenia niche is sustained by unique drug delivery methods. The current quick ratio on this chart confirms financial stability, where the parameter value equals 1.89.

Investors are assessing the resilience of Alkermes plc (ALKS) through the company's ability to immediately settle short-term debts using cash and accounts receivable, completely excluding low-liquidity drug inventories. By analyzing the acid-test ratio, one can determine the extent to which patent income and royalties ensure the financial autonomy of the biopharmaceutical business amid market volatility without the need for emergency liquidation of warehouse stocks.